# A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease

> **NCT03677648** · PHASE2 · COMPLETED · sponsor: **Reistone Biopharma Company Limited** · enrollment: 112 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** SHR0302
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03677648
- **Lead sponsor:** Reistone Biopharma Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-14
- **Primary completion:** 2021-09-16
- **Final completion:** 2021-12-09
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2023-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03677648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03677648, "A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03677648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*